Brochures, Pharmaceutical

Analytical Services in the Development of MDIs and DPIs

Pressurized metered dose inhalers and dry powder inhalers are challenging to develop whether as new drug products or generics. This brochure details the analytical services that Gateway Analytical, a company that specializes in particle characterization and particulate analysis, offers for these vital products in the management and treatment of asthma and COPD. The Gateway Analytical team has regulatory and scientific expertise, extensive experience in pharmaceutical testing and a wide range of instrumentation at its disposal. A defining focus for pressurized metered dose inhaler and dry powder inhaler testing is chemically-specific particle characterization via techniques such as automated Raman Chemical Imaging, Raman Spectroscopy, Laser-induced breakdown spectroscopy, and Scanning Electron Microscopy/Energy Dispersive Spectroscopy.

Via single particle characterization and/or analyses for complete particle populations Gateway Analytical enables scientists to elucidate deagglomeration/dispersion behavior, examine the performance of drug products with multiple actives, and identify foreign contaminants. The analytical services provided support activities from discovery and development, through clinical trials and in-vitro bioequivalence testing to commercial manufacturing and safety monitoring. In this way Gateway Analytical can help you to accelerate the commercialization of your pressurized metered dose inhalers and dry powder inhalers to   ensure these reach commercialization as quickly as possible.

Download Brochure "Analytical Services in the Development of MDIs and DPIs"
25 Nov 2022

Learn more about Aptar Pharma Services

Find Out More About Aptar Pharma Services

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More About pulmonary drug delivery expertise

This Might Also Be of Interest

1 Dec 2019

The Current State of Play in Connected Devices

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
1 Nov 2019

Exploring a Faster, More Cost-Effective Alternative to Generic Bioequivalence

Publications, Pharmaceutical, Innovation & Insights, Product Solutions

Read More
1 Apr 2019

Interview with Guillaume Brouet on Aptar Pharma Services

Publications, Pharmaceutical, Innovation & Insights

Read More
18 Sep 2018

Aptar Pharma provides guidance on FDA regulatory framework for OINDPs

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
1 12 13 14 15

Request Access

Close

Requesting access to Analytical Services in the Development of MDIs and DPIs.

  • This field is for validation purposes and should be left unchanged.
Back To Top